Tepmetko Approved for Treating METex14-Positive NSCLC Patients

Published by W Butcher on

The FDA approved tepotinib (Tepmetko, EMD Serono) following priority review for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal–epithelial transition exon 14 (METex14) skipping alterations. Tepotinib is the first and only FDA-approved MET inhibitor that offers once-daily oral dosing.

Read More…

Categories: Uncategorized